Global oncology firm BeiGene has rebranded as BeOne Medicines Ltd. and completed its redomiciliation from the Cayman Islands to Switzerland.

The move was approved by shareholders on April 28 and marks a strategic pivot to embed the company deeper into Europe’s biopharma landscape.

BeOne will gradually roll out its new name across operations on six continents, reinforcing its global identity.

The company cites Switzerland’s biotech ecosystem as a springboard for its next phase of growth in cancer therapeutics.

BeOne boasts one of the industry’s largest oncology pipelines, with more than 50 investigational assets and aggressive expansion in both hematologic and solid tumor treatments.

Its blood cancer drug BRUKINSA now leads new patient starts in its class in the U.S., while its research team advanced 13 novel cancer drugs into the clinic in 2024 alone.

BeOne’s $800 million R&D and manufacturing site in Hopewell, New Jersey, serves as the company’s U.S. anchor for innovation and production scale.

With over 25,000 patients enrolled in 170+ trials, BeOne positions itself as a cost-efficient oncology juggernaut ready to disrupt the pharmaceutical elite.